The newly developed antibody 6H4 fragments (Fabs) specific to A? oligomers, encapsulated in the polymeric nanomicelles (PMs), were peripherally administrated to AD model mouse for 10 weeks. In mice that were administered anti-A?O 6H4 Fabs in the PMs, various toxic A? species (A? oligomers, A?42s, N3pE A?s, A?s with toxic conformer) and the presence of A? plaques with dense cores in the brain were significantly reduced. Additionally, suppression of the progression of pathological processes of AD was supported by the prevention of cognitive-behavioral decline in the spatial memory tests.
CREDIT: Department of Neurology and Neurological Science, TMDU
Researchers led by Tokyo Medical and Dental University (TMDU) find that antibody fragments encapsulated in nanomicelles cross the blood–brain barrier and reduce the levels of toxic A? species in the brain of an Alzheimer’s disease model mouse
Sometimes the best things in life come by chance, when we happen to be in the right place at the right time. Now, researchers from Japan have found a way to ensure that new medications are delivered to the right place in the body and at the right timepoint in disease progression, so that they have the best effect.
In a study published recently in the Journal of Nanobiotechnology, researchers led by Tokyo Medical and Dental University (TMDU) have revealed that a novel delivery system delivers treatment to where it is needed most in a mouse model of Alzheimer’s disease (AD).
AD is a common neurodegenerative disease that causes dementia. It is characterized by the accumulation of a protein called amyloid ? (A?) in the brain, and a number of different toxic forms of A? have been identified that impair brain function, notably A? oligomers (A?Os).
“Multiple clinical trials have attempted to use an anti-A? antibody to treat AD, but the results have been unsatisfactory,” says lead author of the study Akiko Amano. “One potential explanation for this is that the blood–brain barrier (BBB) prevents most full-length antibodies from entering the brain.”
To address this challenge, the researchers previously developed glucosylated (sugar-linked) polymeric nanomicelles (PMs), which are tiny, hollow balls that could successfully cross the BBB via transcytosis in mouse brain capillary endothelial cells; this process was mediated by glucose-transporter-1 and induced by an increase in blood glucose levels after the mice experienced fasting conditions. In this study, Takanori Yokota and colleagues filled PMs with fragments of an anti-A?O antibody, injected them into a mouse model of AD, and assessed the effects on the brain and on behavior.
“The results were very clear,” explains senior author Nobuo Sanjo. “Administration of anti-A?O antibody fragments through PMs significantly reduced the amounts of various toxic A? species. In addition, the A? plaques that did form were smaller and less dense than those seen in untreated mice.”
Next, the researchers analyzed the behavior of the mice and found that the mice treated with the antibody fragment-filled PMs had better learning and spatial memory than untreated mice. “Our findings suggest that delivering sufficient levels of antibodies to the brain using PMs can reduce toxic A? species and slow AD progression in mice,” says Amano.
Given that the failure of anti-A? antibodies to improve cognitive function in human clinical trials was likely because of an insufficient supply of the antibodies in the brain, PM-encapsulated antibody fragments could represent an effective way to prevent AD progression. In addition, new candidates for AD treatment that degrade toxic A?s and reduce their toxic effects could also be delivered to the brain using the same PM-based system.
Original Article: Transporting antibodies across the blood–brain barrier to treat Alzheimer’s disease
More from: Tokyo Medical and Dental University
The Latest Updates from Bing News
Go deeper with Bing News on:
- Alzheimer’s Association gears up for big June to help raise awareness in Capital Region
June is "Alzheimer's and Brain Awareness Month." The local Alzheimer's Association's mission of educating and raising awareness of the importance of early detection is a yearlong effort, but during ...
- Study Unveils Rare Cannabinoid As Promising Hope For Alzheimer's, Parkinson's & Huntington's Treatment
The company has filed an international patent application for the use of rare cannabinoids and analogs to enhance neuronal function “for the potential treatment of neurodegenerative diseases such as ...
- Medicare plans to pay for Alzheimer's drugs that win full FDA approval
The medication costs $26,500 a year, making it out of reach for most people. But if the advisory committee meeting goes well and the FDA grants traditional approval, people on Medicare who want the ...
- Medicare details plan to cover Alzheimer's treatments
Patients will have to participate in registries that collect real-world data on how the drug works as a condition of coverage.
- Study: Stress granules control Alzheimer's gene transcripts and neuronal proteostasis
A new research paper was published on the cover of Aging, title "Stress granules sequester Alzheimer's disease-associated gene transcripts and regulate disease-related neuronal proteostasis." ...
Go deeper with Bing News on:
PM-encapsulated antibody fragments
- Method created to better remove protein causing Alzheimer’s
The researchers, primarily from Tokyo Medical and Dental University and the Innovation Center of Nanomedicine, encapsulated fragments of an antibody that can attach itself to the protein and ...
- Advances in Antibody Therapeutics
Elina is a PhD candidate at the University of Toronto studying the regulation of microbial shikimate dehydrogenase enzymes. Elina joined the Creative Services Team as an intern and assists with ...
- New Arrows Aimed at Tau: Single-Domain Antibody, Peptibody, Vaccine
Acknowledging that the bulk of tau stays inside cells, some speakers touted single-domain antibodies, small fragments that can more easily enter neurons. Others introduced vaccine strategies designed ...
- Antibody Fragments Market Business Trends To 2031
1. Does this report consider the impact of COVID-19 and the Russia-Ukraine war on the Antibody Fragments market? Yes. As the COVID-19 and the Russia-Ukraine war are profoundly affecting the global ...
- Antibody Fragments Market Size Expects To Cross US$ 13.41 Billion By 2032 With Monoclonal Antibodies Segment To Hold 95% Share X Herald
(MENAFN- Ameliorate Digital Consultancy) The antibody fragments market, currently valued at USD 7.56 billion, is predicted to develop at a compound annual growth rate (CAGR) of 5.9% during the ...